Vapotherm Announces FDA Clearance Of HVT 2.0 - Quick Facts

(RTTNews) - Vapotherm, Inc. (VAPO) has received 510(k) clearance from the FDA for HVT 2.0 which is designed to provide high velocity therapy using an integrated air source. HVT 2.0, when paired with an oxygen source, support patients in need of respiratory support. Vapotherm said it plans a limited commercial release of HVT 2.0 in the U.S. in the fourth quarter of 2021.

"We will use this next generation platform, combined with the Vapotherm Access digital remote Patient monitoring platform, to begin learning how to treat complex lung disease Patients in the home," said Joe Army, CEO of Vapotherm.